Relevance: Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.

Conclusions: GDF15 and semaglutide reduce food intake and body weight through largely distinct processes that produce greater weight loss and feeding suppression when combined. This article is protected by copyright.

Conclusions: GDF15 and semaglutide reduce food intake and body weight through largely distinct processes that produce greater weight loss and feeding suppression when combined. This article is protected by copyright. All rights reserved.

Conclusion: "Adults who have weight related comorbidity and a BMI of at least 35 (or lower under certain circumstances) should be offered the weight loss drug semaglutide alongside a diet and exercise plan, NICE has said."

Conclusions: In a Swedish setting, oral semaglutide was cost effective compared with empagliflozin and sitagliptin for patients with T2D inadequately controlled on oral glucose-lowering drugs.